HC Wainwright Reaffirms Buy Rating for Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $45.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 50.05% from the company’s current price.

Several other equities analysts also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Evercore initiated coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price target on the stock. TD Cowen started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They set a “buy” rating for the company. Royal Bank Of Canada initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 target price on the stock. Finally, Wedbush restated an “outperform” rating and set a $35.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research report on Friday, June 12th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $42.43.

Damora Therapeutics, Inc. Common Stock Trading Down 9.1%

NASDAQ DMRA opened at $29.99 on Tuesday. Damora Therapeutics, Inc. Common Stock has a 12 month low of $2.45 and a 12 month high of $38.33. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -5.37 and a beta of 1.46. The company’s 50 day moving average is $25.36 and its two-hundred day moving average is $25.70.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). Sell-side analysts forecast that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently bought and sold shares of DMRA. Janus Henderson Group PLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $40,000. Geode Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $266,000. Virtu Financial LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at about $49,000. Sigma Planning Corp bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $334,000. Finally, Two Sigma Investments LP purchased a new position in Damora Therapeutics, Inc. Common Stock in the third quarter worth about $76,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.